$BCRX @Heywood_Bablome I suggest you get off the lot move on AMF
BCRX
+0.38 (3.10%)
12.64
| General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Comparison | ||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
News
...
| Is BioCryst Pharmaceuticals Inc (BCRX) Stock at the Top of the Biotechnology Industry? | news.google.com • |
| BioCryst Pharmaceuticals Receives Approval for Orladeyo in Israel | news.google.com • |
| BioCryst Pharma (BCRX) Announces Approval of ORLADEYO by the Israeli Ministry of Health | news.google.com • |
| BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health | news.google.com • |
| 3 Biotechnology stocks under 10 dollars to buy now | thedogofwallstreet.com • |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript | seekingalpha.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-11-01 | 2022-09 | -0.32 | -0.23 | 0.09 | 28.13% |
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-11-02 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| 2022-11-02 | RBC Capital | Upgrade | Sector Perform | |
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-11-13 | BABU YARLAGADDA S | Officer | 298.54K | Sale |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-08-30 | HEGGIE THERESA | Director | 30.63K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-09-29 | Vanguard Group, Inc. (The) | 13.84M | 174.92M | 7.42% |
| 2022-09-29 | Blackrock Inc. | 13.77M | 174.12M | 7.39% |
| 2022-09-29 | Baker Brothers Advisors, LLC | 12.71M | 160.66M | 6.82% |
| 2022-09-29 | State Street Corporation | 9.40M | 118.87M | 5.04% |
| 2022-09-29 | Avoro Capital Advisors LLC | 9.05M | 114.39M | 4.85% |
| 2022-09-29 | FMR, LLC | 5.71M | 72.14M | 3.06% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-10-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.07M | 76.67M | 3.25% |
| 2022-06-29 | Vanguard Total Stock Market Index Fund | 5.47M | 69.09M | 2.93% |
| 2022-08-30 | Fidelity Select Portfolios - Biotechnology | 4.35M | 54.95M | 2.33% |
| 2022-08-30 | iShares Russell 2000 ETF | 4.03M | 50.91M | 2.16% |
| 2022-06-29 | Vanguard Extended Market Index Fund | 2.56M | 32.41M | 1.38% |
| 2022-06-29 | Vanguard Small-Cap Index Fund | 2.33M | 29.40M | 1.25% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
$BCRX @Gunnar1 you haven’t been around since you mentioned covid hope your doing ok…good luck.
-
$BCRX Who is that coconut holding the SeaTurtle?
-
-
$AQST What a bunch of idiots our day will come just keep adding
-
$BCRX @Gunnar 🤙
-
-
-
-
-
$BCRX @Sarath it sounds like you need to liquidate your position if any and move on perhaps the investors @SRNE would value your input.
-
$BCRX Mabe that was nonsense
-
$BCRX This is about the time @Imacocconut shows up with his 2 cents
-
$BCRX @Imacoconut 🖕🏻🫵
-
-
$BCRX I sure hope @Imakook gives us some direction today
-
$BCRX I had 31K shares sitting right here a few day’s ago…does this concern any of you?
-
-
$BCRX Great we’ve got Imacouk sharing knowledge this morning it’s gona be a good day?